Hancock Jaffe Laboratories, Inc. (HJLI): Price and Financial Metrics
GET POWR RATINGS... FREE!
HJLI Stock Summary
- Hancock Jaffe Laboratories Inc's market capitalization of $7,135,019 is ahead of just 3.84% of US-listed equities.
- HJLI's price/sales ratio is 228.37; that's higher than the P/S ratio of 98.53% of US stocks.
- As for revenue growth, note that HJLI's revenue has grown -83.25% over the past 12 months; that beats the revenue growth of just 1.36% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Hancock Jaffe Laboratories Inc are MOTS, NBRV, KALA, RKDA, and ADMP.
- Visit HJLI's SEC page to see the company's official filings. To visit the company's web site, go to www.hancockjaffe.com.
HJLI Stock Price Chart Interactive Chart >
HJLI Price/Volume Stats
|Current price||$9.67||52-week high||$17.68|
|Prev. close||$9.41||52-week low||$4.99|
|Day high||$9.78||Avg. volume||529,798|
|50-day MA||$7.29||Dividend yield||N/A|
|200-day MA||$7.22||Market Cap||83.98M|
Hancock Jaffe Laboratories, Inc. (HJLI) Company Bio
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is based in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Most Popular Stories View All
HJLI Latest News Stream
|Loading, please wait...|
HJLI Latest Social Stream
View Full HJLI Social Stream
Latest HJLI News From Around the Web
Below are the latest news stories about Hancock Jaffe Laboratories Inc that investors may wish to consider to help them evaluate HJLI as an investment opportunity.
Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs
\- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 -\- Development strategy to focus on venous disease and advancement of the VenoValve® -\- Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 -\- Management to host a conference call with live video webcast at 4:30 p. ET today, September 21st -IRVINE, CA / ACCESSWIRE / September 21, 2021 / Hancock Jaffe Laboratorie
Multiple insiders bought Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) stock earlier this year, a positive sign for shareholders
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p. ETIRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc.
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
IRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq rules.
Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) announced two-year data post-VenoValve implantation in eight patients. Data will be presented at the Society for Vascular Surgery (SVS) Annual Meeting. The results showed that the reflux (the backward flow of blood) decreased from 1.95 to an average of .72 (a 63% improvement). Disease manifestations decreased from an average of 13.38 to an average of 5.38 (a 60% improvement). Pain decreased from an average of 7.25 to an average of .50 (an improvement
HJLI Price Returns
Continue Researching HJLIHere are a few links from around the web to help you further your research on Hancock Jaffe Laboratories Inc's stock as an investment opportunity:
Hancock Jaffe Laboratories Inc (HJLI) Stock Price | Nasdaq
Hancock Jaffe Laboratories Inc (HJLI) Stock Quote, History and News - Yahoo Finance
Hancock Jaffe Laboratories Inc (HJLI) Stock Price and Basic Information | MarketWatch